Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Accelerated tumour growth due to immunotherapy: Fact or fiction?

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.04.19
Views: 782

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Dr Marina Garassino speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about increased tumour growth as a result of immunotherapy in hyper-progressive cancer patients.

She addresses the divided opinions regarding this phenomenon - in which some oncologists believe the increased tumour growth seen in these patients is simply a representation of a more aggressive disease. However, other oncologists believe a subset of patients are susceptible to an acceleration in tumour growth.

Dr Garassino describes the discovery of an immune phenotype, characterised by PDL-1/CD33/CD163 expressing macrophages that may exist in these patients.

Dr Garassino also mentions a prospective trial that will aim to examine this phenomenon, along with a pre-clinical study that has reproduced this occurrence in animal models.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation